1 FDA Guidance for Industry: ANDAs: Impurities in Drug Substances www.Rx-360.org Published by US FDA’s Center for Drug Evaluation and Research June 2009.

Slides:

Advertisements

Similar presentations

Regulatory Pathway for Platform Technologies

Advertisements

When is Excipient Reduced Testing Appropriate?

Patent-Extender Drugs: Loop-holes in the Law Sandy H. Yoo 4/14/06.

Quality by Design for Topical Dosage Forms

Statistical Evaluation of Dissolution for Specification Setting and Stability Studies Fasheng Li Associate Director, Pharmaceutical Statistics Worldwide.

2-4 ICH Quality Guidances: an overview

Finished Pharmaceutical Product Specifications

Anticounterfeiting of Solid Oral Dosage Forms Hemant N. Joshi, Ph.D., MBA Tara Innovations LLC Parsippany, NJ

1 Implementation of Quality by Design (QbD): Status, Challenges and Next Steps Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS,

Impurities in New Drug Substances ICH Topic Q3A (R) – Revised Guidelines in Oct الشوائب في الأدوية الجديدة.

Batch Reworking and Reprocessing

Determine impurity level in relevant batches1

FEDERAL REGULATIONS OF MEDICATIONS Food, Drug and Cosmetic Act Protect consumers from adulterated and misbranded foods, drugs, cosmetics, or devices.

Development and Review Process of NDA, ANDA/AADA and OTC Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Associate Professor Department of Pharmaceutics KLE.

Special Topics in IND Regulation

Neonatal/Juvenile Animal Safety Studies Kenneth L. Hastings, Dr.P.H., D.A.B.T. Office of New Drugs, CDER.

Regulatory Requirements with Relevance for Quality of API

COMPARABILITY PROTOCOLS ACPS March 12-13, 2003 Stephen K. Moore, Ph.D. Chemistry Team Leader CDER/Office of New Drug Chemistry Co-Chair, Comparability.

Regulatory requirements on Medicine Stability Guidelines relevant for Stability testing Sultan Ghani.

Regulation of Generic Drugs Office of Generic Drugs Craig Kiester Regulatory Support Branch.

Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Regulatory Requirement on Dossier of Medicinal.

Mrs. Brandi Robinson Office of New Animal Drug Evaluation Center for Veterinary Medicine Regulating Animal Drugs.

Structure of Dossier of Medicinal Product- Q part

1 ACPS November 15, Update Nancy B. Sager, Associate Director Office of Pharmaceutical Science Center for Drug Evaluation & Research Food and.

Product Definition Chapter 4. What is a Medical Device? FDA: “an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent,

Christian Asher.  there are more than 50,000 Dietary supplements available on the market today.  Dietary supplements are more popular than they’ve ever.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Impurities, PQT Training May |1 | S.3.2 Impurities, Malaysia, 29 September 2011 Impurities Dr Antony Fake WHO Prequalification Team - Medicines.

1 Regulatory Concepts for Dual Indication Combination Products Charu Mullick, M.D. Division of Antiviral Products, CDER U.S. Food and Drug Administration.

CVM’s Procedure for Setting Tolerances

Overview of FDA's Regulatory Framework for PET Drugs

Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.

ACPS Advisory Committee Meeting October , 2002 ACPS Advisory Committee Meeting October , 2002 Scientific Considerations of Polymorphism in.

Investigational New Drug Application (IND)

When do I need an IND ? FDA Guidance for Industry – Investigation New Drug Applications (INDs) - Determining Whether Human Research Studies Can Be Conducted.

Risk Based CMC Review Advisory Committee for Pharmaceutical Science October 22, 2003 Vilayat A. Sayeed, Ph.D. OGD, FDA.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Nonclinical Perspective on Initiating Phase 1 Studies for Small Molecular Weight Compounds John K. Leighton, PH.D., DABT Supervisory Pharmacologist Division.

CHEE DRUG PRODUCT DEVELOPMENT u Drug ä agent intended for use in the diagnosis, mitigation, treatment, cure, or prevention of disease in man or animals.

Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.

Compliance with FDA Regulations: Collecting, Transmitting and Managing Clinical Information Dan C Pettus Senior Vice President iMetrikus, Inc.

1 Impurities: Positions of the regulatory authorities (like FDA and EMA) worldwide Dr. Christian Zeine, Warsaw, Nov 18, 2014 Science for a safer world.

Preclinical Guidelines: Development of Radioprotective/Mitigative Agents Departments of Dermatology & Radiation Oncology University of Rochester Medical.

Stability of FPPs- Conducting, Bracketing, Matrixing Sultan Ghani.

Proposed Gluten Regulations in Argentina Excipient Realities and Global Requirements.

Predicting Physical Stability in Q1A(R) Chi-wan Chen, Ph.D. Office of New Drug Chemistry Center for Drug Evaluation and Research Food and Drug Administration.

Overview of FDA's Regulatory Framework for PET Drugs

1/33.  What is INDA ?  Types of INDAs  Objectives of INDAs  Format & Contents of an INDA  IND Safety reports  IND Annual Reports  IND Review Process.

Nutraceuticals & New Dietary Ingredients The Swiss Perspective Willi Hunziker, DVM, MBA

HELM AG Module 3 Christa Clasen Ankara, 6./7. April 2006.

The New Drug Development Process (www. fda. gov/cder/handbook/develop

© AL IPA/EDQM/IDMA Symposium 2007, All rights reserved The Ph. Eur. policy on impurities Dr Andrea Lodi Deputy Head, Laboratory Department, EDQM, Council.

Current Issues & Challenges in the Development of Pharmacopoeial Monographs: Some New Challenges in the Impurities Arena Dr. Susanne Keitel European Directorate.

COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.

General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,

Lawrence X. Yu, Ph.D. Director for Science Office of Generic Drugs, OPS, CDER, FDA ACPS Meeting, ACPS Meeting, Oct. 22, 2003 Office of Generic Drugs Research.

Impurities in Drugs author: srikanth N

Stability Studies : Regulatory evaluation and most frequently observed Sultan Ghani.

VICH Guidelines: Stability Testing of New Veterinary Drug Substances and Medicinal Products Mai Huynh U.S. FDA Center for Veterinary Medicine Washington.

1 IND Applications for Academic Clinical Investigations John Marler, MD US Food and Drug Administration New Hampshire Avenue White Oak, MD

Manufacturing Process of Drug Product: Container closure system Compatibility Ratiya KUKHETPITAKWONG 27 April 2016.

Elemental Impurities– An Update Kahkashan Zaidi, Ph.D. General chapters USP.

Guidance for review of studies involving HCT/Ps and IND Basics

Dorota Matecka, Ph.D. Office of Pharmaceutical Quality (OPQ), CDER

Implementation of Quality by Design (QbD): Status, Challenges and Next Steps Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER.

Opening an IND: Investigator Perspective

Quality guidelines on impurities

Quality guidelines on impurities

GL8 (R) – Stability testing for medicated premixes

Presentation transcript:

1 FDA Guidance for Industry: ANDAs: Impurities in Drug Substances Published by US FDA’s Center for Drug Evaluation and Research June 2009

2 FDA, CDER Guidance on Impurities in Drug Substances Purpose: –Applicable to drug substances produced by chemical synthesis when submitting: Original abbreviated new drug application (ANDAs) Drug master files (DMFs) including type II DMFs ANDA supplements for changes in synthesis or processing of drug substance –Provide guidance for establishing acceptable criteria for impurities –Provides consistency with ICH Q3A guidance for NDAs –Out of scope Fermentation products Radiopharmaceuticals Products of animal origin Biologics/Biotechnological Herbal products Peptides Semisynthetic products derived from fermentation products Oligonucleotide

3 Guidance Content Identification of impurities & acceptable criteria –Listing impurities in Drug Substance Specifications –Setting acceptable criteria for impurities Qualification of Impurities –Qualification thresholds –Qualification procedures

4 Definitions 1 Drug Substance Definition: an active ingredient that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or any function of the human body, but does not include intermediates use in the synthesis of such ingredient. 2 Qualification: The process of acquiring and evaluating data that establish the biological safety of an individual impurity or a given impurity profile at the level(s) being considered. 1 21CFR Guidance for Industry: ANDAs: Impurties in Drug Substances

5 Identification of Impurities Listing of Impurities in Drug Substance Specifications based on: - Stability studies - Chemical development studies - Routine batch analyses Must be based on batch(es) manufactured by the proposed commercial process Rationale for inclusion as well as exclusion

6 Identification of Impurities-continued Types of impurities: Type of Impurities: Identified Impurity? Unidentified Impurity? 1 Unspecified impurity < identified threshold? Total Impurities Organic Residual Solvents Inorganic impurities 1 ICH Q3A

7 Impurity specified in USP? Monograph exists in the USP? Yes: - Utilize limit specified in monograph (official compendial limit) No: - Qualify the impurity - Level based on either reference list drug (RLD) or qualified level Acceptable Criteria for Impurities

8 Qualification of Impurities Qualified only if at least one of the following met: - The observed level and proposed acceptance criterion for the impurity < RLD - Impurity is a significant metabolite of the drug substance - The observed level and the proposed acceptance criterion adequately justified by scientific literature - The observed level and proposed acceptance criteria < safe levels from toxicity studies

9 Thresholds Based on maximum daily dose of drug substance Outlined in Q3A(R) Procedures Comparative Analytical Studies (CAS) Scientific Literature & Significant Metabolites (SLSM) Toxicity Studies (CAS & SLSM preferred) Qualification Thresholds & Procedures

10 Factors that could allow acceptance of studies to qualify the impurity: - Patient population - Daily dose - Route & duration of drug administration Qualification Procedure

11 Martin VanTrieste Advisory Board +1 (805) For More Information Thank you